Halladay Benjamin
Chief Financial Officer
Halladay Benjamin has filed 6 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Jul 13, 2026.
On the most recent filing, Halladay Benjamin is listed as Chief Financial Officer at Esperion Therapeutics, Inc. Inside the rolling window, Halladay Benjamin reported no open-market purchases and 4 open-market sales totaling $98K in ESPR. The largest disclosed transaction in the window is a sale of 10,773 ESPR shares on Jun 17, 2026, worth $34K.
Companies traded
Other insiders at ESPR
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$98K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Halladay Benjamin made?
Halladay Benjamin has filed 6 SEC Form 4 filings (6 transaction rows) across 1 company since 2025.
Which companies does Halladay Benjamin trade?
Halladay Benjamin has filed SEC Form 4 disclosures for 1 company, including ESPR.
When was Halladay Benjamin's most recent SEC Form 4 filing?
Halladay Benjamin's most recent SEC Form 4 filing on Tracefour is dated Jul 13, 2026.
What is Halladay Benjamin's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Halladay Benjamin is listed as Chief Financial Officer.
What is Halladay Benjamin's total buy and sell value in the current window?
Inside the rolling retention window, Halladay Benjamin bought $0 and sold $98K based on SEC Form 4 filings.
What was Halladay Benjamin's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,773 ESPR shares on 2026-06-17, worth $34K, per SEC Form 4 filings.